{"title":"低分割放疗治疗局限性前列腺癌：一项前瞻性临床试验方案。","authors":"Yiyin Liang, Weiwei Zhang, Xianzhi Zhao, Huojun Zhang","doi":"10.1080/14796694.2025.2489340","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Compared to conventional fractionated radiotherapy (CFRT), which delivers lower doses over a longer period, moderate hypofractionated radiotherapy (HFRT) administers higher doses in a shorter period. Increasing evidence has demonstrated that the safety and efficacy of moderate HFRT in 20-28 fractions for localized PCa are equal to those of CFRT. However, the optimal and lowest fractions of moderate HFRT need to be explored for localized PCa. Therefore, this trial aims to investigate the safety outcomes of HFRT in 15 fractions for treating patients with localized PCa.</p><p><strong>Methods and analysis: </strong>This is a single-center, single-arm, open-label clinical trial. Patients with localized PCa will be enrolled to receive HFRT (54 Gy delivered in 15 daily fractions of 3.6 Gy). The primary outcome measures are the incidence of radiotherapy-related gastrointestinal (GI) and genitourinary (GU) symptoms and erectile dysfunction. Secondary outcome measures include biochemical progression-free survival (bPFS), local progression-free survival (LPFS), distant metastasis-free survival (DMFS), overall survival (OS), and quality of life (QoL).</p><p><strong>Clinical trial registration: </strong>NCT06325774 (Clinicaltrials.gov).</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":"21 12","pages":"1483-1488"},"PeriodicalIF":3.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077468/pdf/","citationCount":"0","resultStr":"{\"title\":\"Hypofractionated radiotherapy for localized prostate cancer: the protocol for a prospective clinical trial.\",\"authors\":\"Yiyin Liang, Weiwei Zhang, Xianzhi Zhao, Huojun Zhang\",\"doi\":\"10.1080/14796694.2025.2489340\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Compared to conventional fractionated radiotherapy (CFRT), which delivers lower doses over a longer period, moderate hypofractionated radiotherapy (HFRT) administers higher doses in a shorter period. Increasing evidence has demonstrated that the safety and efficacy of moderate HFRT in 20-28 fractions for localized PCa are equal to those of CFRT. However, the optimal and lowest fractions of moderate HFRT need to be explored for localized PCa. Therefore, this trial aims to investigate the safety outcomes of HFRT in 15 fractions for treating patients with localized PCa.</p><p><strong>Methods and analysis: </strong>This is a single-center, single-arm, open-label clinical trial. Patients with localized PCa will be enrolled to receive HFRT (54 Gy delivered in 15 daily fractions of 3.6 Gy). The primary outcome measures are the incidence of radiotherapy-related gastrointestinal (GI) and genitourinary (GU) symptoms and erectile dysfunction. Secondary outcome measures include biochemical progression-free survival (bPFS), local progression-free survival (LPFS), distant metastasis-free survival (DMFS), overall survival (OS), and quality of life (QoL).</p><p><strong>Clinical trial registration: </strong>NCT06325774 (Clinicaltrials.gov).</p>\",\"PeriodicalId\":12672,\"journal\":{\"name\":\"Future oncology\",\"volume\":\"21 12\",\"pages\":\"1483-1488\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2025-05-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12077468/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Future oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/14796694.2025.2489340\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/21 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2489340","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/21 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
Hypofractionated radiotherapy for localized prostate cancer: the protocol for a prospective clinical trial.
Purpose: Compared to conventional fractionated radiotherapy (CFRT), which delivers lower doses over a longer period, moderate hypofractionated radiotherapy (HFRT) administers higher doses in a shorter period. Increasing evidence has demonstrated that the safety and efficacy of moderate HFRT in 20-28 fractions for localized PCa are equal to those of CFRT. However, the optimal and lowest fractions of moderate HFRT need to be explored for localized PCa. Therefore, this trial aims to investigate the safety outcomes of HFRT in 15 fractions for treating patients with localized PCa.
Methods and analysis: This is a single-center, single-arm, open-label clinical trial. Patients with localized PCa will be enrolled to receive HFRT (54 Gy delivered in 15 daily fractions of 3.6 Gy). The primary outcome measures are the incidence of radiotherapy-related gastrointestinal (GI) and genitourinary (GU) symptoms and erectile dysfunction. Secondary outcome measures include biochemical progression-free survival (bPFS), local progression-free survival (LPFS), distant metastasis-free survival (DMFS), overall survival (OS), and quality of life (QoL).
期刊介绍：
Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community.
The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
